Mankind Pharma (MANKIND) Share Price Fall Streak: stock declines for second straight session
- October 9, 2026
- Posted by: Kunal Singla
- Category: News
Mankind Pharma Share Price Fall Streak is in focus as the stock traded lower in its second straight session, with the cumulative move across the streak at -5.95% from Rs 2,494.85. At 09 October 2026 at 9:53:20 AM IST, the latest traded price was Rs 2,346.50. The price move is confirmed in Univest data; a company-specific reason has not been established.
The company’s market capitalisation stood at Rs 1,03,048.55 crore, which keeps it in the Large Cap category. For readers tracking Mankind Pharma Share Price Fall Streak, the key point is not only the one-session move but the fact that two lower sessions in a row change the way the stock is read versus a single-day decline. That streak context matters because the re-pricing is now measured across more than one session, while the underlying operating base has not changed within this short window.
Mankind Pharma (MANKIND) Share Price Fall Streak: Consecutive Decline Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,346.5 |
| Previous Close | Rs 2,398.4 |
| Today's Move | -Rs 51.90 (-2.16%) |
| Open | Rs 2,379.65 |
| High | Rs 2,389 |
| Low | Rs 2,340.75 |
| Market Capitalisation | Rs 1,03,048.55 crore |
Mankind Pharma Share Price Fall Streak continued through a weak intraday path, with the stock last traded at Rs 2,346.50 versus the previous close of Rs 2,398.40. The move translated into a fall of Rs 51.90, or 2.16%, and the day opened at Rs 2,379.65. During the session, the stock touched a high of Rs 2,389.00 and a low of Rs 2,340.75.
The latest traded price sat near the lower end of that range, which keeps Mankind Pharma Share Price Fall Streak in clear view for intraday readers. The company’s market capitalisation remained Rs 1,03,048.55 crore, so this is a Large Cap stock even after the decline. Mankind Pharma Share Price has now moved lower across two straight sessions, and the cumulative fall from the streak start base price of Rs 2,494.85 stands at 5.95%. That sequence is more informative than one session alone because it shows how the lower prices have followed each other without interruption.
What the Consecutive Declines Show
Mankind Pharma Share Price Fall Streak now reflects a second straight lower session, and that makes the move more than a one-off intraday slip. The cumulative decline of 5.95% from Rs 2,494.85 shows where the stock now stands relative to the start of the streak, while the latest price action confirms that the market is still adjusting the price lower across sessions.
For Mankind Pharma Share Price Fall Streak, the useful read is simple: the current move is best understood as a run of consecutive lower sessions rather than an isolated one-day event. The latest traded price, the prior close and the streak base price together show how the repricing has developed. According to Univest data, the price pattern is confirmed, but no company-specific catalyst is established.
Mankind Pharma (MANKIND) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,03,048.55 crore |
| P/E Ratio | 48.5x |
| P/B Ratio | 5.89x |
| ROE | 12.69% |
| ROCE | 13.24% |
| EPS | Rs 49.45 |
| Book Value Per Share | Rs 407.39 |
| Dividend Yield | 0.04% |
Mankind Pharma (MANKIND) fundamental metrics show P/E 48.5x, P/B 5.89x, ROE 12.69%, ROCE 13.24%. These ratios show where the company stands today and are not a call to buy or sell.
Mankind Pharma has a market capitalisation of Rs 1,03,048.55 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 48.5x, P/B at 5.89x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 12.69% and ROCE of 13.24%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 49.45, book value per share of Rs 407.39, dividend yield of 0.04%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 31.28x, median ROE of 11.61%, median ROCE of 13.46%. Together they describe the fundamental backdrop without implying a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 48.5x |
| Benchmark Median P/E | 31.28x |
| Benchmark Average P/E | 47.09x |
| Benchmark P/E Range | 3.56x to 678.22x |
| Company P/B Ratio | 5.89x |
| Benchmark Median P/B | 2.85x |
| Benchmark Average P/B | 4.25x |
| Company ROE | 12.69% |
| Benchmark Median ROE | 11.61% |
| Benchmark Average ROE | 10.59% |
| Company ROCE | 13.24% |
| Benchmark Median ROCE | 13.46% |
| Benchmark Average ROCE | 13.36% |
| Company Market Capitalisation | Rs 1,03,048.55 crore |
| Benchmark Median Market Cap | Rs 821.44 crore |
| Benchmark Average Market Cap | Rs 14,054.13 crore |
Mankind Pharma (MANKIND) operates in the Healthcare sector, within the Pharmaceuticals & Drugs industry.
Mankind Pharma (MANKIND) has a P/E ratio of 48.5x, which is above the benchmark median of 31.28x, a difference of +55.05%. A P/E difference of this kind is a reference point rather than a recommendation.
Mankind Pharma (MANKIND) has a ROE of 12.69%, which is above the benchmark median of 11.61%, a difference of +9.3%. Mankind Pharma (MANKIND) has a ROCE of 13.24%, which is below the benchmark median of 13.46%, a difference of -1.63%.
Track stocks among today's decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,27,861.41 | 34.76 | 4.86 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,54,318.9 | 85.21 | 14.11 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,79,153.26 | 81.53 | 19.81 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,15,111.94 | 24.65 | 4.13 | 19.69 | 21.39 |
| Laurus Labs | LAURUSLABS | 1,11,034.16 | 98.83 | 19.16 | 18.31 | 18.2 |
Mankind Pharma (MANKIND) has a P/E ratio of 48.5x compared with the displayed peer median of 81.53x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 12.69% compares with a peer median of 18.31% across the companies shown in the table. ROCE stood at 13.24% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Mankind Pharma (MANKIND) has a market capitalisation of Rs 1,03,048.55 crore. All 5 peers shown have a larger market capitalisation.
Why Investors Are Watching Mankind Pharma
- Mankind Pharma Share Price Fall Streak has now extended to a second straight session, so the decline is being read across more than one trading day.
- The latest traded price of Rs 2,346.50 is still below the previous close of Rs 2,398.40, keeping Mankind Pharma Share Price under pressure in the near term.
- The cumulative fall of 5.95% from Rs 2,494.85 gives the streak a clear price reference beyond the latest session alone.
- Valuation remains notable, with a P/E ratio of 48.5 and a P/B ratio of 5.89 even after the decline.
- Sector and peer comparisons show the stock trading at richer multiples than several healthcare names, while return ratios remain mixed.
About Mankind Pharma
Mankind Pharma operates in the Pharmaceuticals & Drugs industry within Healthcare. It is a Large Cap company by market value, and that size makes Mankind Pharma Share Price Fall Streak more relevant for readers who track large healthcare names rather than smaller, less liquid counters. The business context that matters here is the company’s position in a sector where valuation and profitability are often compared closely across listed peers.
For Mankind Pharma Share Price Fall Streak, the most useful company background is simple: the stock belongs to a large Indian pharmaceutical business that is now being judged alongside sector peers on valuation, returns and price action. That is enough context to understand why the current decline is drawing attention.
Track Mankind Pharma Share Price on Univest
Use Mankind Pharma (MANKIND) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
You can track Mankind Pharma Share Price on Univest for live price updates, fundamental ratios, 52-week levels and market insights. Univest also keeps the Large Cap context, valuation ratios and peer comparison in one place, so readers can follow Mankind Pharma Share Price Fall Streak alongside broader stock analysis.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Mankind Pharma Share Price falling today?
Ans. According to Univest data, the stock is trading lower in its second straight session, with a 2.16% fall to Rs 2,346.50. The confirmed price pattern is clear, but no company-specific catalyst is established.
What is Mankind Pharma Share Price today?
Ans. The latest traded price was Rs 2,346.50 as of 09 October 2026 at 9:53:20 AM IST. That was below the previous close of Rs 2,398.40 and keeps Mankind Pharma Share Price Fall Streak in focus.
How much has Mankind Pharma fallen across the streak?
Ans. The cumulative fall across the second straight session streak is 5.95% from the streak start base price of Rs 2,494.85. That makes the move more meaningful than a single-day decline on its own.
What were the day high and day low for Mankind Pharma ?
Ans. The stock touched a high of Rs 2,389.00 and a low of Rs 2,340.75 during the session. The latest traded price sat close to the lower end of that range, which keeps the decline visible.
What is Mankind Pharma market capitalisation?
Ans. Mankind Pharma had a market capitalisation of Rs 1,03,048.55 crore. That places it in the Large Cap category and makes the current move important for readers tracking sizeable healthcare names.
How is Mankind Pharma valued versus the sector?
Ans. The stock trades at a P/E of 48.5 and a P/B of 5.89, both above the same-industry benchmark median. Even after the decline, Mankind Pharma Share Price Fall Streak leaves valuation above the industry midpoint.
What do ROE and ROCE show for Mankind Pharma ?
Ans. ROE stands at 12.69% and ROCE at 13.24%. ROE is above the industry benchmark median, while ROCE is slightly below it, so the return profile is mixed rather than uniformly stronger.
How does Mankind Pharma compare with peers?
Ans. The company’s market value is close to Dr. Reddy’s Laboratories and above Aurobindo Pharma, but below Sun Pharmaceutical Industries and Torrent Pharmaceuticals Its P/E is also above several peers shown here.
Should investors track Mankind Pharma Share Price on Univest?
Ans. Yes. Univest tracks live price action, fundamental ratios, 52-week levels and market insights in one place. That helps readers follow Mankind Pharma Share Price Fall Streak alongside valuation, sector and peer context.
